Literature DB >> 26104452

Using Plasmids as DNA Vaccines for Infectious Diseases.

John S Tregoning, Ekaterina Kinnear.   

Abstract

DNA plasmids can be used to induce a protective (or therapeutic) immune response by delivering genes encoding vaccine antigens. That naked DNA (without the refinement of coat proteins or host evasion systems) can cross from outside the cell into the nucleus and be expressed is particularly remarkable given the sophistication of the immune system in preventing infection by pathogens. As a result of the ease, low cost, and speed of custom gene synthesis, DNA vaccines dangle a tantalizing prospect of the next wave of vaccine technology, promising individual designer vaccines for cancer or mass vaccines with a rapid response time to emerging pandemics. There is considerable enthusiasm for the use of DNA vaccination as an approach, but this enthusiasm should be tempered by the successive failures in clinical trials to induce a potent immune response. The technology is evolving with the development of improved delivery systems that increase expression levels, particularly electroporation and the incorporation of genetically encoded adjuvants. This review will introduce some key concepts in the use of DNA plasmids as vaccines, including how the DNA enters the cell and is expressed, how it induces an immune response, and a summary of clinical trials with DNA vaccines. The review also explores the advances being made in vector design, delivery, formulation, and adjuvants to try to realize the promise of this technology for new vaccines. If the immunogenicity and expression barriers can be cracked, then DNA vaccines may offer a step change in mass vaccination.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 26104452     DOI: 10.1128/microbiolspec.PLAS-0028-2014

Source DB:  PubMed          Journal:  Microbiol Spectr        ISSN: 2165-0497


  21 in total

1.  DNA vaccine expressing herpes simplex virus 1 glycoprotein C and D protects mice against herpes simplex keratitis.

Authors:  Li-Li Dong; Ru Tang; Yu-Jia Zhai; Tejsu Malla; Kai Hu
Journal:  Int J Ophthalmol       Date:  2017-11-18       Impact factor: 1.779

2.  An effective DNA vaccine platform for Middle East respiratory syndrome coronavirus.

Authors:  Adam S Cockrell; Ralph S Baric
Journal:  Ann Transl Med       Date:  2016-12

3.  Airway T cells protect against RSV infection in the absence of antibody.

Authors:  E Kinnear; L Lambert; J U McDonald; H M Cheeseman; L J Caproni; J S Tregoning
Journal:  Mucosal Immunol       Date:  2017-05-24       Impact factor: 7.313

Review 4.  Adjuvanted influenza vaccines.

Authors:  John S Tregoning; Ryan F Russell; Ekaterina Kinnear
Journal:  Hum Vaccin Immunother       Date:  2018-01-25       Impact factor: 3.452

5.  A Comparison of Red Fluorescent Proteins to Model DNA Vaccine Expression by Whole Animal In Vivo Imaging.

Authors:  Ekaterina Kinnear; Lisa J Caproni; John S Tregoning
Journal:  PLoS One       Date:  2015-06-19       Impact factor: 3.240

6.  DNA Vaccines Encoding Antigen Targeted to MHC Class II Induce Influenza-Specific CD8(+) T Cell Responses, Enabling Faster Resolution of Influenza Disease.

Authors:  Laura Lambert; Ekaterina Kinnear; Jacqueline U McDonald; Gunnveig Grodeland; Bjarne Bogen; Elisabeth Stubsrud; Mona M Lindeberg; Agnete Brunsvik Fredriksen; John S Tregoning
Journal:  Front Immunol       Date:  2016-08-23       Impact factor: 7.561

7.  Multi-walled carbon nanotubes functionalized with recombinant Dengue virus 3 envelope proteins induce significant and specific immune responses in mice.

Authors:  Alice F Versiani; Ruiz G Astigarraga; Eliseu S O Rocha; Ana Paula M Barboza; Erna G Kroon; Milene A Rachid; Daniele G Souza; Luiz O Ladeira; Edel F Barbosa-Stancioli; Ado Jorio; Flávio G Da Fonseca
Journal:  J Nanobiotechnology       Date:  2017-04-04       Impact factor: 10.435

8.  An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1.

Authors:  Julie L Dutton; Wai-Ping Woo; Janin Chandra; Yan Xu; Bo Li; Neil Finlayson; Paul Griffin; Ian H Frazer
Journal:  Hum Vaccin Immunother       Date:  2016-12       Impact factor: 3.452

Review 9.  Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges.

Authors:  Idris Nasir Abdullahi; Anthony Uchenna Emeribe; Hafeez Aderinsayo Adekola; Sharafudeen Dahiru Abubakar; Amos Dangana; Halima Ali Shuwa; Sunday Theophilus Nwoba; Jelili Olaide Mustapha; Muyideen Titilope Haruna; Kafayat Adepeju Olowookere; Olawale Sunday Animasaun; Charles Egede Ugwu; Solomon Oloche Onoja; Abdullahi Sani Gadama; Musa Mohammed; Isa Muhammad Daneji; Dele Ohinoyi Amadu; Peter Elisha Ghamba; Nkechi Blessing Onukegbe; Muhammad Sagir Shehu; Chiladi Isomah; Adamu Babayo; Abdurrahman El-Fulaty Ahmad
Journal:  Hum Vaccin Immunother       Date:  2020-09-16       Impact factor: 3.452

10.  A Multi-Component Prime-Boost Vaccination Regimen with a Consensus MOMP Antigen Enhances Chlamydia trachomatis Clearance.

Authors:  Alexander Badamchi-Zadeh; Paul F McKay; Bette T Korber; Guillermo Barinaga; Adam A Walters; Alexandra Nunes; João Paulo Gomes; Frank Follmann; John S Tregoning; Robin J Shattock
Journal:  Front Immunol       Date:  2016-04-28       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.